EUVIMEDEUVIMED entdecken
Multizentrische Studie

Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab

Shimpei Yamashita iD, Shuzo Hamamoto iD, Junya Furukawa, Kazutoshi Fujita, Masayuki Takahashi, Makito Miyake iD, Noriyuki Ito, Hideto Iwamoto, Yasuo Kohjimoto, Isao Hara

Japanese Journal of Clinical Oncology · 01.06.2024 · 54 (6) · 722-729

DOI: 10.1093/jjco/hyae031 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 14.03.2024. Verfasst von Shimpei Yamashita und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Wakayama Medical University, Wakayama, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Ipilimumab, Nivolumab, Kidney Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Lung immune prognostic index is based on derived neutrophil-to-lymphocyte ratio and lactate dehydrogenase level. Lung immune prognostic index has reported association with survival outcomes in patients with various malignancies undergoing treatment with immune checkpoint inhibitors. However, the prognostic impact of pre-treatment lung immune prognostic index in patients with metastatic renal cell carcinoma receiving nivolumab plus ipilimumab treatment remains unclear. This study examines the association between lung immune prognostic index and outcomes in this setting.

Methods

We retrospectively evaluated 156 patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab at eight institutions. We assessed the associations between pre-treatment lung immune prognostic index and survival outcomes including progression-free survival, second progression-free survival (PFS2), cancer-specific survival and overall survival.

Results

Patients were classified into good (n = 84, 54%), intermediate (n = 52, 33%) and poor (n = 20, 13%) lung immune prognostic index groups. Progression-free survival did not significantly differ between lung immune prognostic index groups, but there was significant difference in PFS2, cancer-specific survival and overall survival. In multivariable Cox proportional hazard analyses, high pre-treatment lung immune prognostic index was a significant predictor of poor PFS2 (vs. good group, intermediate group: P = 0.01 and poor group: P = 0.04) and poor overall survival (vs. good group, intermediate group: P = 0.01 and poor group: P < 0.01). Moreover, the patients with poor lung immune prognostic index had significantly poorer cancer-specific survival than those with good LIPI (P < 0.01).

Conclusions

High pre-treatment LIPI is suggested by our results to be a significant independent predictor of poor prognosis in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellIpilimumabNivolumabKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsLung NeoplasmsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedPrognosisAdultAged, 80 and overNeutrophils

Stichwörter der Autor:innen

PD-1 inhibitorbiomarkerscytotoxic T lymphocyte-associated antigen 4 inhibitorprognosisrenal cancer

Substanzen

IpilimumabNivolumab

Autor:innen und Institutionen

  • Department of Urology, Wakayama Medical University, Wakayama, Japan.
  • Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Japan.
  • Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Department of Urology, Nara Medical University, Kashihara, Nara, Japan.

ORCID-Profile: Shimpei Yamashita, Shuzo Hamamoto, Makito Miyake

Zitieren

APA

Yamashita, S., Hamamoto, S., Furukawa, J., Fujita, K., Takahashi, M., Miyake, M., Ito, N., Iwamoto, H., Kohjimoto, Y., & Hara, I. (2024). Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Japanese Journal of Clinical Oncology, 54(6), 722-729. https://doi.org/10.1093/jjco/hyae031

Vancouver

Yamashita S, Hamamoto S, Furukawa J, Fujita K, Takahashi M, Miyake M, et al. Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Japanese Journal of Clinical Oncology. 2024;54(6):722-729. doi:10.1093/jjco/hyae031

BibTeX
@article{Yamashita2024,
  author = {Yamashita, Shimpei and Hamamoto, Shuzo and Furukawa, Junya and Fujita, Kazutoshi and Takahashi, Masayuki and Miyake, Makito and Ito, Noriyuki and Iwamoto, Hideto and Kohjimoto, Yasuo and Hara, Isao},
  title = {Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2024},
  volume = {54},
  number = {6},
  pages = {722--729},
  doi = {10.1093/jjco/hyae031}
}
Kostenlos starten →